Want to see IN:THEMISMED full AI Analyst Report?
THEMISMED Stock Chart & Stats
₹102.50
₹17.25(6.68%)
At close: 4:00 PM EST
₹102.50
₹17.25(6.68%)
Day’s Range― - ―
52-Week Range₹65.00 - ₹147.99
Previous CloseN/A
Volume256.77K
Average Volume (3M)6.87K
Market Cap
₹9.69B
Enterprise Value₹13.23K
Total Cash (Recent Filing)₹91.50M
Total Debt (Recent Filing)₹1.00B
Price to Earnings (P/E)809.4
Beta1.45
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.48%
Share Statistics
EPS (TTM)0.13
Shares Outstanding92,100,120
10 Day Avg. Volume6,301
30 Day Avg. Volume6,868
Financial Highlights & Ratios
PEG Ratio-5.72
Price to Book (P/B)1.58
Price to Sales (P/S)1.84
P/FCF Ratio-37.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryA 33.9% top-line increase indicates renewed demand or successful commercial execution, improving capacity utilization and providing a platform to rebuild margins. Durable revenue momentum supports working-capital normalization and gives management time to address cost structure over several quarters.
Manageable LeverageLow-to-moderate debt (D/E ~0.25) preserves financial flexibility, limiting refinancing and interest-rate stress. This balance-sheet headroom allows the company to absorb temporary cash-flow weakness, fund corrective investments or working capital, and reduces the risk of forced asset sales in the near term.
Manufacturing & Multi-channel Sales ModelAn integrated manufacturing model serving commercial, institutional and export channels creates diversified demand sources and repeat institutional contracts. This structural commercial mix supports predictable volumes, scale advantages, and revenue resilience versus single-channel peers over 2–6 months.
Bears Say
Severe Margin CompressionA dramatic drop in gross margin and negative EBIT margin point to structural cost pressures, adverse product mix, or pricing erosion. Such a wide swing undermines the company’s ability to generate operating profits and fund reinvestment, making recovery reliant on sustained pricing or cost fixes over multiple quarters.
Negative Operating & Free Cash FlowMaterial negative OCF and FCF reverse prior cash generation and elevate funding risk. Persistent cash outflows can force external financing, constrain R&D and capex, and impair supplier relationships. Without margin or working-capital improvement, cash deficits are likely to persist across the near-term reporting periods.
Collapsed Return On EquityROE near zero signals capital is not generating meaningful returns, reflecting weak profit conversion despite sizable equity. Persistently low ROE reduces capacity to attract capital and limits options for growth investments, requiring operational turnaround or capital restructuring to restore shareholder returns.
Themis Medicare Limited News
THEMISMED FAQ
What was Themis Medicare Limited’s price range in the past 12 months?
Themis Medicare Limited lowest stock price was ₹65.00 and its highest was ₹147.99 in the past 12 months.
What is Themis Medicare Limited’s market cap?
Themis Medicare Limited’s market cap is ₹9.69B.
When is Themis Medicare Limited’s upcoming earnings report date?
Themis Medicare Limited’s upcoming earnings report date is Aug 13, 2026 which is in 4 days.
How were Themis Medicare Limited’s earnings last quarter?
Themis Medicare Limited released its earnings results on May 28, 2026. The company reported ₹0.96 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Themis Medicare Limited overvalued?
According to Wall Street analysts Themis Medicare Limited’s price is currently Overvalued.
Does Themis Medicare Limited pay dividends?
Themis Medicare Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.48%. See more information on Themis Medicare Limited dividends here
What is Themis Medicare Limited’s EPS estimate?
Themis Medicare Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Themis Medicare Limited have?
Themis Medicare Limited has 92,100,120 shares outstanding.
What happened to Themis Medicare Limited’s price movement after its last earnings report?
Themis Medicare Limited reported an EPS of ₹0.96 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Themis Medicare Limited?
Currently, no hedge funds are holding shares in IN:THEMISMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Themis Medicare Limited
Themis Medicare Limited, along with its affiliated entities, is a pharmaceutical company that produces and supplies medicinal goods for both the Indian and international markets. Its product portfolio encompasses active pharmaceutical ingredients (APIs) and various drug formulations, designed for application across diverse medical domains such as anti-infectious conditions, malaria, tuberculosis, cardiovascular issues, health and wellness, cancer, eye diseases, and pain relief. Founded in 1969, the company operated under the name Themis Chemicals until 2001, when it officially changed to Themis Medicare Limited. The company's primary operations are directed from its Mumbai, India headquarters.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Jagsonpal Pharmaceuticals Ltd.
―
Venus Remedies Limited
―
Wanbury Limited
―
Zim Laboratories Ltd.
―